CAS: 187618-60-6; Fmoc-D-Arg(Pbf)-Oh

该化合物是一种复杂的有机化合物,其复杂结构包括一个D-onithine脊柱,一个磺酰胺组以及各种芳香和静态的次组.这种化合物具有一种苯丙胺的特征,有助于其潜在的生物活动,以及一种在peptide合成中常用的氟乙酰氟氧基碳基(Fmoc)保护组.多种甲基组的存在增强了其脂性,有可能影响其溶性以及与生物膜的相互作用.磺基氨基质组可能适用于医药化学,特别是在针对特定生物途径的药品研制过程中.

结构式图片

相似化合物

154445-77-9 200124-22-7 200115-86-2

欧盟法规

C&L通报REACH预注册

上下游产品

(fluorenylmethoxy)carbonyl chloride N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimideFm°C-L-Arg-OH

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2023331778-A1
    优先权日:2020-08-31
    标 题 :An improved process for fmoc synthesis of etelcalcetide
    发明人:LOBO LESTER JOHN; CHANDRAKESAN MURALIDHARAN; DOSHI CHETAN; CHANADAK SHAILESH LALCHAND; YADAV NANDLAL GOPAL; MOHE NIKHIL UMESH; VISHWANATHAN KODANDARAMAN; CHAVRE PRAFUL SHAMRAO
    权利人:USV PRIVATE LTD
    摘要:The present invention relates to an improved process for the synthesis of Etelcalcetide and its analogs by solid phase synthesis of Fmoc protected amino acids in a sequential manner, followed by acetylation of terminal D-cys and cleavage of peptide from solid support. The crude heptapeptide thus obtained is reduced using Tris(2-carboxyethyl) phosphine hydrochloride, purified and oxidized with L-cysteine. The oxidized Etelcalcetide is purified and salt exchanged using a one-step reverse phase chromatography process. The purified Etelcalcetide hydrochloride is then precipitated using organic solvents, concentrated and lyophilized to purity of greater than 99.0%.

    专利号:US-2020247841-A1
    优先权日:2017-09-27
    标 题 :Synthesis of icatibant
    发明人:RAMU VASANTHAKUMAR GANGA; PATIL NITIN SOPANRAO; PALLE VENTAKA RAGHAVENDRACHARYUL; Yogesha
    权利人:BIOCON LTD
    摘要:The present invention relates to the efficient solid-phase synthesis of Icatibant represented by Formula (I). The present invention relates to an efficient process for the preparation of Icatibant by sequential coupling employing solid phase approach. It involves sequential coupling of protected amino acids to prepare Icatibant. The present invention also involves the usage of inorganic salts during the coupling, wash with HOBt in DMF solution after Fmoc-deprotection step to ensure complete removal of piperidine and reactions are going for completion, and thus avoid addition/deletion sequences and also improve the process yield.

    专利号:EP-3875466-A1
    优先权日:2020-03-05
    标 题 :Process for the synthesis of etelcalcetide
    发明人:MARTELLI GIULIA; CABRI WALTER; FERRAZZANO LUCIA; VIOLA ANGELO; TOLOMELLI ALESSANDRA; RICCI ANTONIO
    权利人:FRESENIUS KABI IPSUM S R L; ALMA MATER STUDIORUM UNIV OF BOLOGNA
    摘要:The present invention provides a manufacturing process for etelcalcetide through direct disulfide bond formation with N-chlorosuccinimide in high yield and high purity.

    专利号:US-10899791-B2
    优先权日:2017-10-03
    标题 :Method for synthesizing etelcalcetide or salts thereof
    发明人:LEE KWANG-CHUNG; HSIEH KUANG-CHAN; CHENG HUI-WEN; KAO CHIA-SUI; HUANG YA-LING; WANG WEI-SSU
    权利人:CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO LTD
    摘要:The present invention provides a method for synthesizing etelcalcetide or salts thereof, comprising the steps of: (a) synthesizing the D-amino acids in the formula (I) sequentially by Fmoc solid-phase synthesis, using a solid support as a starting material in solid phase peptide synthesis and sequentially synthesizing a D-form amino acid of formula (I) by Fmoc chemistry; deprotecting Fmoc group and acetylating the amino group to obtain a sequence A comprising protecting groups (PG) in the side chain of D-Cys and D-Arg; (b) removing the protecting group in the side-chain of D-Cys of the sequence A to form a sequence B; (c) disulfide formation at D-Cys of the sequence B by (PG)-L-Cys-OH to obtain a sequence C; (d) using a cleavage solution to remove the protecting groups of the sequence C to give etelcalcetide as formula (I). The present invention can shorten the steps and time for preparing Etelcalcetide.

    专利号:US-11420997-B2
    优先权日:2018-04-13
    标题:Peptide synthesis method
    发明人:SUZUKI HIDEAKI; MUTO SUSUMU; FUJITA SHUJI; KUBO DAISUKE
    权利人:JITSUBO CO LTD
    摘要:The present invention has an object of shortening the process time and reducing use of a poor solvent for solidifying a carrier (Tag)-peptide component, by removing impurities without conducting solid-liquid separation (condensation, solid-liquid separation and drying operation) of a Tag-peptide component, in an Fmoc method using a Tag for liquid phase peptide synthesis. Provided is the peptide synthesis method that includes the following steps a-d: step a: a carrier-protected amino acid, carrier-protected peptide, or a carrier-protected amino acid amide, and an N-Fmoc-protected amino acid or an N-Fmoc-protected peptide are condensed in an organic solvent or a mixed solution of organic solvents, to obtain an N-Fmoc-carrier-protected peptide, step b: a water-soluble amine is added to the reaction solution after the condensation reaction, step c: the Fmoc group is deprotected from the protected amino group in the presence of a water-soluble amine, and step d: the reaction solution is neutralized by adding an acid, and further, by adding and washing with an acidic aqueous solution, then, by liquid-liquid separation an aqueous layer is removed to obtain an organic layer.

    专利号:US-2024209034-A1
    优先权日:2021-04-12
    标题:Engineering peptides for a a vb6 integrin binding and related methods of use and synthesis
    发明人:SELLERS DREW; CARDLE IAN; PUN SUZIE HWANG
    权利人:UNIV WASHINGTON; SEATTLE CHILDRENS HOSPITAL D/B/A SEATTLE CHILDRENS RES INSTITUTE
    摘要:Embodiments of the claimed invention are directed to synthetic peptides comprising an amino acid sequence of X 1 X 2 VX 3 NLRGDLQVLX 4 QKVCX 5 T (SEQ ID NO:18), wherein at least one of X 1 and X 2 is a cysteine, and wherein one or more of X 3 , X 4 , and X 5 is a non-natural amino acid. Also described are methods of using the claimed embodiments for inhibiting growth of a cancer cell overexpressing integrin αvβ6. Additionally, also described are methods of using the claimed embodiments for detecting a cancer cell overexpressing integrin αvβ6.
    常州吉恩药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.genchem.cn
    企业联系电话:18861157601;18861157609👤
    📞常州吉恩药业有限公司 ⚠️参考联系方式
    联系人:吉恩销售
    电话:18861157601;18861157609
    手机:18861157609
    传真:0519-85720007
    邮箱:sales02@genchem.cn
    通信地址: 江苏省常州市新北区滨江经济开发区玉龙北路658号
    邮编: 213127
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏省常州市新北区滨江经济开发区玉龙北路658号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    天津科创医药中间体技术生产力促进有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.scipharmacn.com
    企业联系电话:022-60116533👤
    📞天津科创医药中间体技术生产力促进有限公司 ⚠️参考联系方式
    联系人:王经理
    电话:022-60116533
    手机:13207668525
    传真:022-60979672
    邮箱:saleskc@scipharmacn.com
    通信地址: 天津市华苑产业园区(环外)海泰发展六道6号海泰绿色产业基地
    邮编: 300118
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:天津市华苑产业园区(环外)海泰发展六道6号海泰绿色产业基地
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献

    [参考文献]: Luckose F, Et Al. Effects Of Amino Acid Derivatives On Physical, Mental, And Physiological Activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.

    合成参考文献

    合成方法参考DOI号:10.1055/s-0034-1378379
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知